Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Common Equity (2016 - 2025)

Ascendis Pharma A's Common Equity history spans 8 years, with the latest figure at -$156.8 million for Q4 2023.

  • For Q4 2023, Common Equity fell 158.34% year-over-year to -$156.8 million; the TTM value through Dec 2023 reached -$156.8 million, down 158.34%, while the annual FY2023 figure was -$157.6 million, 156.78% down from the prior year.
  • Common Equity for Q4 2023 was -$156.8 million at Ascendis Pharma A, down from $268.7 million in the prior quarter.
  • Across five years, Common Equity topped out at $1.0 billion in Q4 2021 and bottomed at -$156.8 million in Q4 2023.
  • The 5-year median for Common Equity is $660.9 million (2019), against an average of $556.7 million.
  • The largest annual shift saw Common Equity surged 106.77% in 2019 before it plummeted 158.34% in 2023.
  • A 5-year view of Common Equity shows it stood at $660.9 million in 2019, then surged by 51.3% to $1000.0 million in 2020, then rose by 1.09% to $1.0 billion in 2021, then crashed by 73.42% to $268.7 million in 2022, then crashed by 158.34% to -$156.8 million in 2023.
  • Per Business Quant, the three most recent readings for ASND's Common Equity are -$156.8 million (Q4 2023), $268.7 million (Q4 2022), and $1.0 billion (Q4 2021).